Cargando…

CLRM-07 A MULTIVARIATE RETROSPECTIVE ANALYSIS OF 159 PATIENTS WITH HIGH-GRADE GLIOMAS: OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL, AND PROGNOSTIC FACTORS

BACKGROUND AND PURPOSE: High-grade gliomas are highly malignant, aggressive, high incidence rate, and mortality. The purpose of this study was to analyze retrospectively and identify prognostic factors of patients with high-grade gliomas diagnosed by biopsy or postoperative pathological examination....

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Shiyu, Jiang, Xin, Dong, Lihua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354228/ http://dx.doi.org/10.1093/noajnl/vdac078.027

Ejemplares similares

CLRM-20 IDENTIFYING RISK FACTORS AND ANALYZING SURVIVAL FOLLOWING PACHYMENINGEAL FAILURE
por: Kalyvas, Aristotelis, et al.
Publicado: (2022)

CLRM-13. INTRAOPERATIVE MICRODIALYSIS: GLIOMA INTELLIGENCE FROM BEHIND ENEMY LINES
por: Riviere-Cazaux, Cecile, et al.
Publicado: (2021)

CLRM-06 PROSPECTIVE CLINICAL STUDY OF CONVENTIONALLY FRACTIONATED CONCURRENT CHEMORADIOTHERAPY AND HYPOFRACTIONATED CONCURRENT CHEMORADIOTHERAPY AFTER THE SURGERY OF HIGH-GRADE GLIOMAS
por: Weiyan, Shi
Publicado: (2022)

CLRM-05. DRUG-RELEASING MICRODEVICES TO PREDICT RESPONSES TO TARGETED THERAPIES IN PATIENTS WITH GLIOMAS
por: Blitz, Sarah, et al.
Publicado: (2021)

CLRM-05 FEASIBILITY OF EVALUATING ABEMACICLIB NEUROPHARMACOKINETICS OF DIFFUSE MIDLINE GLIOMA USING INTRATUMORAL MICRODIALYSIS
por: Dalmage, Mahalia, et al.
Publicado: (2022)

CLRM-14 INTRATUMORAL EXTRACELLULAR METABOLIC IMPACT OF DFMO AND AMXT 1501 IN LIVE HUMAN GLIOMAS
por: Riviere-Cazaux, Cecile, et al.
Publicado: (2022)

CLRM-03 INCIDENCE OF INTRACRANIAL HEMORRHAGE IN GLIOMA PATIENTS WITH VENOUS THROMBOEMBOLISM CONVERTED FROM LMWH TO APIXABAN
por: Aboud, Orwa, et al.
Publicado: (2022)

CLRM-07. INCREASING EFFICIENCY IN EARLY PHASE MULTICENTER IMAGING BIOMARKER TRIALS: EMERGING STRATEGIES FROM THE GABLE (GLIOBLASTOMA ACCELERATED BIOMARKER LEARNING ENVIRONMENT) TRIAL
por: Barboriak, Daniel, et al.
Publicado: (2021)

CLRM-08. TRIAL WORKING GROUPS FOR PAEDIATRIC BRAIN TUMOURS
por: Rahman, Ruman, et al.
Publicado: (2021)

CLRM-07 RANO 2.0: PROPOSAL FOR AN UPDATE TO THE RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (RANO) CRITERIA FOR HIGH- AND LOW-GRADE GLIOMAS IN ADULTS
por: Wen, Patrick, et al.
Publicado: (2023)

CLRM-03. BGB-290 AND TEMOZOLOMIDE IN TREATING ISOCITRATE DEHYDROGENASE (IDH)1/2-MUTANT GRADE I-IV GLIOMAS – A NOVEL MODEL OF AYA TRIAL DEVELOPMENT AND DEPLOYMENT
por: Marks, Asher, et al.
Publicado: (2021)

CLRM-18 SCREEN FAILURES IN PHASE III GLIOBLASTOMA CLINICAL TRIALS
por: Peters, Katherine
Publicado: (2022)

CLRM-11 CURRENT STATE OF CLINICAL TRIALS FOR PATIENTS WITH MELANOMA BRAIN METASTASES
por: Elghawy, Omar, et al.
Publicado: (2022)

CLRM-01 SUMMARY OF VIRTUAL TUMOR BOARD PLATFORMS AND IMPLEMENTATION IN NEURO-ONCOLOGY
por: Ekhator, Chukwuyem, et al.
Publicado: (2022)

CLRM-12. HYBRID DESIGNS FOR USING EXTERNAL CONTROLS IN PHASE 3 GLIOBLASTOMA TRIALS
por: Polley, Mei-Yin, et al.
Publicado: (2021)

CLRM-19 USING FUNCTIONAL PRECISION MEDICINE TO GUIDE CLINICAL TRIAL ENROLLMENT IN GBM
por: Ledford, Aubrey, et al.
Publicado: (2022)

CLRM-01. MACHINE LEARNING TO UNCOVER SIGNATURES OF VULNERABILITY IN GLIOBLASTOMA UMBRELLA SIGNATURE TRIAL (GUST)
por: Peng, Sen, et al.
Publicado: (2021)

CLRM-09. INCORPORATING EXTERNAL CONTROL ARM IN MDNA55 RECURRENT GLIOBLASTOMA REGISTRATION TRIAL
por: Davi, Ruthanna, et al.
Publicado: (2021)

Prognostic Factors of Atypical Meningioma: Overall Survival Rate and Progression Free Survival Rate
por: Lee, Jae Ho, et al.
Publicado: (2017)

CLRM-11. BENCH TO BEDSIDE NEURO-ONCOLOGY: ADVOCATING FOR A CLINICALLY RELEVANT STRATEGY AS UNDERSCORED BY THE PANDEMIC
por: Brown, Timothy, et al.
Publicado: (2021)

CLRM-17 USE OF EXTERNAL CONTROL DATA FOR PLANNING AND ANALYZING GBM TRIALS: READY FOR PRIME TIME?
por: Polley, Mei-Yin, et al.
Publicado: (2022)

RADI-07. Individualized Nomogram for Predicting Survival of Patients with Brain Metastases after Stereotactic Radiosurgery
por: Wen, Lei, et al.
Publicado: (2021)

Prognostic factors for progression‐free and overall survival in malignant pleural mesothelioma
por: Guzmán‐Casta, Jordi, et al.
Publicado: (2021)

CLRM-13 RELEVANCE OF RECURSIVE PARTITIONING ANALYSIS (RPA) CLASSIFICATION IN THE CURRENT CARE OF PATIENTS WITH BRAIN METASTASES (BMETS)
por: Sarai, Guneet, et al.
Publicado: (2022)

STMO-6 Impact of the extent of resection on the survival of patients with lower grade gliomas using awake brain mapping
por: Motomura, Kazuya, et al.
Publicado: (2021)

A prognostic signature based on snoRNA predicts the overall survival of lower-grade glioma patients
por: Zhou, Yi, et al.
Publicado: (2023)

Machine learning classifiers for predicting 3-year progression-free survival and overall survival in patients with gliomas after surgery
por: Zhang, Bin, et al.
Publicado: (2021)

Prognostic nomogram that predicts progression-free survival and overall survival of patients with ovarian clear cell carcinoma
por: Li, Jiayi, et al.
Publicado: (2022)

CLRM-21 RISK FACTORS ASSOCIATED WITH THE PRESENCE OF BRAIN METASTASIS AT THE MOMENT OF DIAGNOSIS IN LUNG CANCER PATIENTS: RETROSPECTIVE CASE SERIES
por: Martín-Abreu, Carla M, et al.
Publicado: (2022)

SYST-07 WINDOW-OF-OPPORTUNITY STUDY OF ONC201 IN PEDIATRIC PATIENTS WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND THALAMIC GLIOMA
por: Odia, Yazmin, et al.
Publicado: (2022)

Progression-free or overall survival…revisited in BOLERO-2
por: Gupta, Sudeep
Publicado: (2014)

LOCL-07 LOCO-REGIONAL INFUSION OF GB-13 (IL13.E13K-PE4E) AS A POTENTIALLY PROMISING TREATMENT FOR RECURRENT HIGH-GRADE GLIOMA
por: Rechberger, Julian, et al.
Publicado: (2022)

CLRM-04. PHASE I/II SAFETY AND EFFICACY STUDY OF BET BROMODOMAIN INHIBITOR OTX-015 WITH OLAPARIB AND LOMUSTINE IN PATIENTS WITH RECURRENT GLIOBLASTOMA
por: Lam, Fred
Publicado: (2021)

CLRM-02 SINGLE CENTER EXPERIENCE OF DOPAMINE ANTAGONIST ONC-201 FOR RECURRENT H3K27M-MUTANT GLIOBLASTOMA IN ADULTS
por: Ekhator, Chukwuyem, et al.
Publicado: (2022)

The Clinical Frailty Scale as predictor of overall survival after resection of high-grade glioma
por: Klingenschmid, Julia, et al.
Publicado: (2022)

Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival
por: Rochefort, Pauline, et al.
Publicado: (2017)

Prognostic significance of sarcopenia diagnosed based on the anthropometric equation for progression-free survival and overall survival in patients with colorectal cancer
por: Xie, Hailun, et al.
Publicado: (2023)

CLRM-09 FIRST-LINE Tumor TREATING FIELDS (200 KHZ) THERAPY FOR NEWLY-DIAGNOSED GLIOBLASTOMA: THE PHASE 3 TRIDENT TRIAL (EF-32)
por: Shi, Wenyin, et al.
Publicado: (2022)

Overall survival and disease-free survival in endometrial cancer: prognostic factors in 276 patients
por: Tejerizo-García, Álvaro, et al.
Publicado: (2013)

Prognostic Factors Affecting Disease-Free Survival and Overall Survival in T4 Colon Cancer
por: Eom, Taeyeong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vsgg6savqgjtvn48ggjdtc61o9